company background image
OPK logo

OPKO Health NasdaqGS:OPK Stock Report

Last Price

US$1.20

Market Cap

US$836.4m

7D

24.4%

1Y

-17.8%

Updated

29 Mar, 2024

Data

Company Financials +

OPK Stock Overview

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.

OPK fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

OPKO Health, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for OPKO Health
Historical stock prices
Current Share PriceUS$1.20
52 Week HighUS$2.24
52 Week LowUS$0.85
Beta1.8
1 Month Change21.77%
3 Month Change-20.53%
1 Year Change-17.81%
3 Year Change-72.60%
5 Year Change-54.02%
Change since IPO-73.33%

Recent News & Updates

Recent updates

OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar

Dec 30
OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar

Is OPKO Health (NASDAQ:OPK) A Risky Investment?

Oct 03
Is OPKO Health (NASDAQ:OPK) A Risky Investment?

OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up

Jul 24
OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up

Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?

Jun 07
Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?

Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?

Jan 04
Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?

OPKO Health: Assessing If Significant Potential Can Be Realized

Sep 15

OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt

Sep 05
OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt

OPKO Health: 14%+ Short Interest Means More Volatility Over The Near Term

Jun 21

OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt

Apr 29
OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt

OPKO Health: A Great Long-Term Investment In Health

Apr 05

OPKO Health Is Risky But Might Make You Money

Mar 29

Analysts Have Just Cut Their OPKO Health, Inc. (NASDAQ:OPK) Revenue Estimates By 14%

Feb 27
Analysts Have Just Cut Their OPKO Health, Inc. (NASDAQ:OPK) Revenue Estimates By 14%

OPKO Health (NASDAQ:OPK) Has A Pretty Healthy Balance Sheet

Jan 12
OPKO Health (NASDAQ:OPK) Has A Pretty Healthy Balance Sheet

OPKO Health: Undervalued Opportunity

Dec 23

OPKO Health: Bullish Case Still Intact

Dec 15

We Think OPKO Health (NASDAQ:OPK) Can Stay On Top Of Its Debt

Sep 27
We Think OPKO Health (NASDAQ:OPK) Can Stay On Top Of Its Debt

OPKO Health: A Defensive, Long-Term Holding

Sep 19

Shareholder Returns

OPKUS HealthcareUS Market
7D24.4%1.1%0.2%
1Y-17.8%9.4%28.1%

Return vs Industry: OPK underperformed the US Healthcare industry which returned 9.4% over the past year.

Return vs Market: OPK underperformed the US Market which returned 28.1% over the past year.

Price Volatility

Is OPK's price volatile compared to industry and market?
OPK volatility
OPK Average Weekly Movement14.1%
Healthcare Industry Average Movement7.4%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: OPK's share price has been volatile over the past 3 months.

Volatility Over Time: OPK's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
19913,930Phil Frosthttps://www.opko.com

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency.

OPKO Health, Inc. Fundamentals Summary

How do OPKO Health's earnings and revenue compare to its market cap?
OPK fundamental statistics
Market capUS$836.39m
Earnings (TTM)-US$188.86m
Revenue (TTM)US$863.50m

1.0x

P/S Ratio

-4.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OPK income statement (TTM)
RevenueUS$863.50m
Cost of RevenueUS$634.96m
Gross ProfitUS$228.53m
Other ExpensesUS$417.40m
Earnings-US$188.86m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.27
Gross Margin26.47%
Net Profit Margin-21.87%
Debt/Equity Ratio17.9%

How did OPK perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.